Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07549451 Imetelstat Myelodysplastic-Myeloproliferative Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07549451 clinical trial report covering Imetelstat, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600123531 Thalidomide Histiocytosis, Langerhans-Cell Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600123531 clinical trial report covering Thalidomide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600123501 Albumin-Bound Paclitaxel Urothelial Carcinoma of the Urinary Bladder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600123501 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
NCT07551739 HSK55718 Pain, Postoperative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07551739 clinical trial report covering HSK55718, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07552012 AC-201 Non-infectious posterior uveitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07552012 clinical trial report covering AC-201, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07552077 Sirolimus Angiokeratoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07552077 clinical trial report covering Sirolimus, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600123538 Acetaminophen Pain, Postoperative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600123538 clinical trial report covering Acetaminophen, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07552324 Polatuzumab Vedotin-Piiq Diffuse Large B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07552324 clinical trial report covering Polatuzumab Vedotin-Piiq, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07551804 Y-shape pegylated somatropin (Xiamen Amoytop Biotech) Growth hormone deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07551804 clinical trial report covering Y-shape pegylated somatropin (Xiamen Amoytop Biotech), Phase 2, endpoints, sponsor, geography, readout timing an
Latest Hotspot
8 min read
CTR20261651 Ifinatamab deruxtecan Metastatic Esophageal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20261651 clinical trial report covering Ifinatamab deruxtecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07553065 NT-201 Urinary Incontinence Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07553065 clinical trial report covering NT-201, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07551596 Botensilimab MSS/pMMR/MSI-L Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07551596 clinical trial report covering Botensilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.